IRVINE, Calif.--(BUSINESS WIRE)--Ivantis, Inc., developer of the novel Hydrus™ Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today announced that the international HYDRUS II trial met its primary endpoint by a wide margin. Results of the randomized, controlled study showed that the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device, significantly reduced intraocular pressure (IOP) and medication use in patients with open angle glaucoma undergoing cataract surgery 24 months post-operatively. The data were presented by Thomas W. Samuelson, MD in a paper presentation at AAO 2014, the annual meeting of the American Academy of Ophthalmology (AAO).
Help employers find you! Check out all the jobs and post your resume.
